21:28 , Nov 10, 2017 |  BC Week In Review  |  Company News

Boehringer, MiNA strike NASH development deal

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with MiNA Therapeutics Ltd. (London, U.K.) to develop therapeutics to treat fibrotic liver disease using MiNA’s small activating RNA (saRNA) technology. The partners' deal is worth up to €307...
21:17 , Nov 10, 2017 |  BC Week In Review  |  Company News

Boehringer, Dicerna in deal to develop NASH candidates

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) partnered with Boehringer Ingelheim GmbH (Ingelheim, Germany) to discover and develop RNAi-based therapeutics to treat non-alcoholic steatohepatitis (NASH) using Dicerna's GalXC platform. Dicerna received $10 million upfront and is eligible for up...
23:48 , Nov 8, 2017 |  BC Extra  |  Company News

Boehringer, MiNA strike NASH development deal

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with MiNA Therapeutics Ltd. (London, U.K.) to develop fibrotic liver disease therapeutics based on MiNA’s small activating RNA (saRNA) technology in a deal worth up to €307 million ($355.7...
22:34 , Nov 2, 2017 |  BC Extra  |  Company News

Boehringer, Dicerna in deal to develop NASH candidates

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) shot up $1.59 (28%) to $7.23 Thursday after it partnered with Boehringer Ingelheim GmbH (Ingelheim, Germany) to discover and develop RNAi-based therapeutics to treat non-alcoholic steatohepatitis (NASH) using Dicerna's GalXC platform. Dicerna...
18:09 , Aug 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggesting inhibiting LOXL2 could help treat metastatic breast cancer. In a mouse model of breast cancer, mammary gland-specific knockout of LOXL2 decreased lung metastatic burden and the number circulating tumor cells...
19:12 , Jun 14, 2017 |  BC Innovations  |  Translation in Brief

Connecting microbiome dots

Although bacteriophages are viruses that infect bacteria, new work from the Human Microbiology Institute suggests bacteriophages may also underly a variety of human diseases by infecting the gut microbiome. At this month’s American Society for...
00:51 , Jan 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Heart failure Patient sample and mouse studies suggest inhibiting LOXL2 could help treat heart failure. LOXL2 levels were higher in serum samples from heart failure patients and cardiac tissue samples from cardiomyopathy patients than in...
07:00 , Jun 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Lysyl oxidase-like 2 (LOXL2)

Cancer INDICATION: Breast cancer Mouse studies suggest inhibiting LOXL2 could help treat breast cancer. In a xenograft mouse model of breast cancer, an anti-LOXL2 antibody decreased tumor growth and the number of lung metastases compared with vehicle....
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

PXS4728A: Phase Ib data

Data from 24 healthy volunteers in the Phase Ib portion of the double-blind, placebo-controlled, Australian Phase Ia/Ib PXS-4728A-101 trial showed that once-daily 3-10 mg oral PSX-4728A for 14 days were well tolerated. Pharmaxis previously reported...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Company News

Pharmaxis, Synairgen deal

Synairgen and Pharmaxis partnered to develop a lysyl oxidase-like 2 (LOXL2) inhibitor to treat idiopathic pulmonary fibrosis (IPF). Synairgen will provide funding and its BioBank platform of advanced human tissue models. The partners will...